BioAge Labs, Inc. ( (BIOA) ) has released its Q3 earnings. Here is a breakdown of the information BioAge Labs, Inc. presented to its investors.

Detailed price information for Bioage Labs Inc (BIOA-Q) from The Globe and Mail including charting and trades.

Inc. ("BioAge", “the Company”), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging, today ...

BioAge is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. BioAge’s lead ...

Shares of BioAge Labs (BIOA), a biopharmaceutical company focused on obesity drugs, opened 25% above its initial public offering (IPO) price on Thursday. RICHMOND, Calif., Sept. 25, 2024 (GLOBE ...

As of the last twelve months ending Q2 2024, BioAge's market capitalization stands at $854.6 million, reflecting investor interest in its innovative approach to treating obesity. Despite the positive ...

Inc. ("BioAge"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging, today announced ...